• PYC Therapeutics requests trading halt pending announcement on proposed capital raising
• Trading halt to be lifted on or before market open on Wednesday, 19 February 2025
• PYC is a biotechnology company developing RNA therapies for inherited eye diseases and other conditions

PYC Therapeutics Ltd (ASX: PYC) has requested an immediate trading halt on its securities pending an announcement to the market regarding a proposed capital raising. The company anticipates that the trading halt will be lifted on or before market open on Wednesday, 19 February 2025 by provision of an announcement to ASX regarding the proposed capital raising. PYC is a biotechnology company creating a new generation of RNA therapies by combining its drug design capabilities with a proprietary drug delivery platform. The company is leveraging its leading-edge science to develop a pipeline of novel therapies including two programs focused on inherited eye diseases and pre-clinical discovery programs focused on neurodevelopmental and kidney diseases. PYC's discovery, pre-clinical and laboratory operations are in Australia and its translational, clinical, and regulatory operations are in the United States.